From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
Despite the 340B certification and audit process, compliance and revenue leakage is a growing fiduciary risk. Manufacturers lack controls and transparency to all relevant sales, product movement, and discounts aligned by covered entity and contract pharmacy. Some hospital systems are voluntarily settling with manufacturers in advance of CMS Final Rule on 340B, but manufacturers lack data to negotiate settlements.
Traditional syndicated datasets contain gaps and can be difficult to align with chargeback data to identify revenue loss. The inability to identify contract pharmacy lines in 867 data, along with issues arising from blinded or blocked portions of that data, can limit broader use of these datasets for analysis.
IntegriChain Revenue Analytics leverages its best-in-class channel master data and analytics to deliver an unparalleled unified view of how patients access products. These datasets offer an unparalleled, unified view of commercial and 340B transactions across all covered entities, sites of care, owned pharmacies, and contract pharmacies to address today’s revenue analysis data challenges. Using your 867 data, enriched with IntegriChain un-blinding and master data, you can visualize 340B trends and forecasts, detect 340B abuse and audit targets, support the audit and settlement process, and identify incorrectly priced returns. With Revenue Analytics, you can access, visualize, and analyze data to answer:
Sales & Marketing Questions
Finance & Audit Questions
Patient Journey Questions
Contact us today to learn more about how IntegriChain can help you analyze your revenue streams and monitor discounted drug purchases and revenue leakage: 609.806.5005
